**Technology Advisory Committee B Interests Register**

**ID3748 Daratumumab in combination for untreated systemic amyloid light-chain amyloidosis [ID3748]**

**Publication Date: XX/XX/XXXX**

| Name | Role with NICE | Type of interest | Description of interest | Interestarose | Interestdeclared | Interest ceased | Comments |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Ashutosh Wechalekar | Clinical expert | Direct – financial | Honorarium from Janssen for Advisory board for daratumumabTravel support and honorarium for meeting/lectures from Janssen |  |  | N/A | It was agreed that these declarations would not prevent Ashtosh from providing expert advice to the committee. |
| Ashutosh Wechalekar | Clinical expert | Direct – non-financial  | On ANDROMEDA trial management group |  |  | N/A | It was agreed that these declarations would not prevent Ashtosh from providing expert advice to the committee. |
| Dr Mamta Garg | Clinical expert | Direct - Financial | Received speaker fees for time spent in advisory meeting for Janssen, Amgen, Novartis Takeda etc in the field of myeloma MPN and ITP.Received speaker fees part in educational activities organised by pharmaceutical company including JanssenReceived small research grants to support services in Leicester Hospitals in the field of MGUS and diagnostics. |  |  | N/A | It was agreed that these declarations would not prevent Mamta from providing expert advice to the committee. |
| Dr Mamta Garg | Clinical expert | Financial interest | Received speaker fees for time spent in advisory meeting for Janssen, Amgen, Novartis Takeda etc in the field of myeloma MPN and ITP. Dr Gary has also received speaker fees part in educational activities organised by pharmaceutical company including Janssen, and small research grants to support services in Leicester Hospitals in the field of MGUS and diagnostics. |  | 10/10/22 | N/A | It was agreed that these declarations would not prevent Dr Gary from providing expert advice to the committee. |
| Professor Nicholas Latimer | TAC Committee Member | Non-financial professional and personal interest | In October 2021 he was paid to give Novartis staff a training session on survival analysis. This was not product or appraisal specific and was about methods. Novartis are listed as a comparator company. |  | 26/09/22 | N/A | It was agreed that this declaration would not prevent Professor Latimer from taking part in this discussion. |
| Dr Charles Crawley | TAC Committee Member | Non-financial professional and personal interest | His professional practice includes care patients with amyloidosis |  | 28/09/22 | N/A | It was agreed that this declaration would not prevent Dr Crawley from taking part in this discussion. |
| Peter Wheatley-Price | TAC Committee Member | Direct financial interest | His employer – Takeda - manufacture ixazomib which is a direct competitor to daratumumab in various lines of therapy in Multiple Myeloma. There are also trials listed on clinicaltrials.gov investigating ixazomib in amyloidosis. |  | 26/09/22 | N/A | It was agreed that this declaration would prevent Peter Wheatley-Price from taking part in this discussion. |

**GUIDANCE NOTES FOR COMPLETION OF THE INTERESTS REGISTER**

**Relevant dates:** Detail here the date the interest arose, the date it was first declared and when it ceased, if applicable. For example, if an individual has ceased to hold shares or undertake relevant private practice.